var data={"title":"Digoxin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Digoxin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6030?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=digoxin-drug-information\" class=\"drug drug_general\">see &quot;Digoxin: Drug information&quot;</a> and <a href=\"topic.htm?path=digoxin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Digoxin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160142\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Digitek;</li>\n      <li>Digox;</li>\n      <li>Lanoxin;</li>\n      <li>Lanoxin Pediatric</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160143\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Digoxin;</li>\n      <li>Digoxin Injection CSD;</li>\n      <li>Lanoxin;</li>\n      <li>Pediatric Digoxin CSD;</li>\n      <li>PMS-Digoxin;</li>\n      <li>Toloxin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052266\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiarrhythmic Agent, Miscellaneous</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Cardiac Glycoside</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15163298\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Dosage must be individualized due to substantial individual variation and must take into account renal function. Doses should be based on lean body weight. When changing from oral solution to IV therapy, dosage should be reduced by 20% to 25%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heart failure:</b> Injection, Oral solution: The dosage tables below list dosage recommendations for normal renal function and are based upon average patient response; patients with decreased renal function require decreased doses, especially patients with end-stage renal disease (ESRD).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Digitalizing dose, initial regimen (optional): </b> Total digitalizing dose should be divided (see below). Digitalizing dose (loading dose) may not be necessary; consider use if rapid titration is desired. To avoid toxicity, consider doses at lower end of the recommended range; dosage should be individualized based on patient response (eg, clinical response, serum drug levels).</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Dosage Recommendations for Digitalizing Dose<sup>A</sup> (Optional)</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Total Digitalizing Dose</p>\n            <p style=\"text-indent:0em;\">Administer in 3 divided doses<sup>B</sup></p>\n            <p style=\"text-indent:0em;\">(mcg/kg)</p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Oral</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">IV<sup>C</sup></p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"3\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>A</sup>Based on lean body weight and normal renal function for age.</p></td></tr>\n        <tr>\n          <td colspan=\"3\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>B</sup>Do not give full total digitalizing dose (TDD) at once. Give one-half of the TDD for the initial dose, then give one-quarter of the TDD for each of 2 subsequent doses at 6- to 8-hour intervals; prior to additional doses, clinical response should be fully evaluated (eg, ECG).</p></td></tr>\n        <tr>\n          <td colspan=\"3\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>C</sup>May also be administered IM; however, not usually recommended.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Preterm neonates</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 to 30</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15 to 25</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Full-term neonates</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25 to 35</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 to 30</p></td></tr></tbody></table>\n    \n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Maintenance Dosage Recommendations for Digoxin<sup>A,B</sup></caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Total Daily Maintenance Dose</p>\n            <p style=\"text-indent:0em;\">Administer in equal divided doses every 12 hours</p>\n            <p style=\"text-indent:0em;\">(mcg/kg/day)</p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Oral</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">IV<sup>C,D</sup></p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"3\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>A</sup>Dosing reflects clinical practice and in some cases, varies from manufacturer labeling (Bakir 1994; Bendayan 1983; Latifi 2000; Park 1986).</p></td></tr>\n        <tr>\n          <td colspan=\"3\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>B</sup>Based on lean body weight and normal renal function for age. Decrease maintenance dose in patients with decreased renal function.</p></td></tr>\n        <tr>\n          <td colspan=\"3\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>C</sup>Daily maintenance IV dose is typically 20% to 30% of total IV digitalizing dose.</p></td></tr>\n        <tr>\n          <td colspan=\"3\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>D</sup>May also be administered IM; however, not usually recommended.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Preterm neonates</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 to 7.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4 to 6</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Full-term neonates</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 10</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 to 8</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tachyarrhythmias (eg, supraventricular tachycardia), prevention: </b>Limited data available: Term neonates: Oral solution: Initial digitalizing dose: 20 to 40 mcg/kg divided every 8 hours for 2 to 3 doses followed by maintenance dose: 8 to 10 mcg/kg/day divided every 12 hours (Kugler 1996; O'Sullivan 1995; Sanatani 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>Use caution in patients with decreased renal function. Patients with decreased renal function require decreased doses, especially patients with ESRD; no recommendations exist for pediatric patients with ESRD; however, it is recommended to decrease total digitalizing and maintenance doses by 50% in adult patients with ESRD (Aronoff 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052258\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=digoxin-drug-information\" class=\"drug drug_general\">see &quot;Digoxin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:<b> Note: </b>Dosage must be individualized due to substantial individual variation and must take into account renal function. Doses should be based on lean body weight. When changing from oral solution to IV therapy, dosage should be reduced by 20% to 25%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heart failure:</b> Injection, Oral solution, Tablet: Infants, Children, and Adolescents: The dosage tables below list dosage recommendations for normal renal function and are based upon average patient response; lower doses are needed for patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Digitalizing dose, initial regimen (optional):</b> Total digitalizing dose should be divided (see below); digitalizing dose (loading dose) may not be necessary; consider use if rapid titration is desired. To avoid toxicity, consider doses at lower end of the recommended range; dosage should be individualized based on patient response (eg, clinical response, serum drug levels).</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Dosage Recommendations for Digitalizing Dose<sup>A</sup> (Optional)</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th colspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">Total Digitalizing Dose</p>\n            <p style=\"text-indent:0em;\">Administer in 3 divided doses<sup>B</sup></p>\n            <p style=\"text-indent:0em;\">(mcg/kg)</p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Oral Solution</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Tablets</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">IV<sup>C</sup></p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"4\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>A</sup>Based on lean body weight and normal renal function for age.</p></td></tr>\n        <tr>\n          <td colspan=\"4\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>B</sup>\n              <b>Do not give full total digitalizing dose (TDD) at once.</b> Give one-half of the TDD for the initial dose, then give one-quarter of the TDD for each of 2 subsequent doses at 6- to 8-hour intervals; prior to additional doses, clinical response should be fully evaluated (eg, ECG).</p></td></tr>\n        <tr>\n          <td colspan=\"4\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>C</sup>May also be administered by IM; however, not recommended.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 24 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">35 to 60</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&minus;</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 to 50</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 to 5 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 to 45</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&minus;</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25 to 35</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 to 10 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 to 35</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 to 45</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15 to 30</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;10 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 to 15</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 to 15</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 12</p></td></tr></tbody></table>\n    \n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Maintenance Dosage Recommendations for Digoxin<sup>A,B</sup></caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th colspan=\"3\" align=\"center\">\n            <p style=\"text-indent:0em;\">Daily Maintenance Dose</p>\n            <p style=\"text-indent:0em;\">If &le;10 years, administer in equal divided doses twice daily</p>\n            <p style=\"text-indent:0em;\">If &gt;10 years, administer once daily</p>\n            <p style=\"text-indent:0em;\">(mcg/kg/day)</p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Oral Solution</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Tablets</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">IV<sup>C,D</sup></p></th></tr></thead>\n      <tfoot valign=\"middle\">\n        <tr>\n          <td colspan=\"4\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>A</sup>Dosing reflects clinical practice and in some cases, varies from manufacturer labeling (Bakir 1994; Bendayan 1983; Latifi 2000; Park 1986).</p></td></tr>\n        <tr>\n          <td colspan=\"4\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>B</sup>Based on lean body weight and normal renal function for age. Decrease maintenance dose in patients with decreased renal function.</p></td></tr>\n        <tr>\n          <td colspan=\"4\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>C</sup>May also be administered by IM; however, not recommended.</p></td></tr>\n        <tr>\n          <td colspan=\"4\" valign=\"middle\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>D</sup>Daily maintenance IV dose is typically 20% to 30% of total digitalizing IV dose in pediatric patients &le;24 months and 25% to 35% in older pediatric patients.</p></td></tr></tfoot>\n      <tbody valign=\"middle\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 to 24 months</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10 to 15</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&minus;</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">9 to 15</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 to 5 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8 to 10</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&minus;</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6 to 9</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 to 10 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5 to 10</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6 to 12</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4 to 8</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;10 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5 to 5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5 to 5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 to 3</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tachyarrhythmias, treatment:</b> Limited data available (Escudero 2012): Injection, Oral solution: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial (digitalizing dose):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 10 to 12 mcg/kg/dose every 8 hours for 3 doses</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 13 to 17 mcg/kg/dose every 8 hours for 3 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: Oral: 8 to 10 mcg/kg/day divided once or twice daily (Escudero 2012); use twice daily dosing in infants and young children (O'Sullivan)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Adult: <b>Note:</b> When changing from oral (tablets or liquid) or IM to IV therapy, dosage should be reduced by 20% to 25%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Atrial fibrillation (rate control):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Total digitalizing dose (TDD): IV: 8 to 12 <b>mcg</b>/kg; administer half of TDD over 5 minutes with the remaining portion as 25% fractions at 4 to 8 hour intervals (ACLS [Neumar 2010]) <b>or</b> may administer 0.25 mg with repeat dosing to a maximum of 1.5 mg over 24 hours followed by an oral maintenance regimen (AHA/ACC/HRS [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: Oral: 0.125 to 0.25 mg once daily (AHA/ACC/HRS [January 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heart failure: Note:</b> Loading dose not recommended; Daily maintenance dose: Oral: 0.125 to 0.25 mg once daily; higher daily doses (up to 0.5 mg/day) are rarely necessary. If patient is &gt;70 years old, has impaired renal function, or has a low lean body mass, low doses (eg, 0.125 mg daily or every other day) should be used initially (ACCF/AHA [Yancy 2013]. <b>Note:</b> IV. digoxin may be used to control ventricular response in patients with atrial fibrillation and heart failure with reduced ejection fraction (HFrEF) who do not have an accessory pathway or preexcitation syndrome (AHA/ACC/HRS [January 2014]). The addition of a beta-blocker to digoxin is usually more effective in controlling ventricular response, particularly during exercise (ACCF/AHA [Yancy 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Supraventricular tachyarrhythmias (rate control):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: Total digitalizing dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 0.75 to 1.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV, IM: 0.5 to 1 mg (<b>Note:</b> IM not preferred due to severe injection site pain.)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Give <sup>1</sup>/<sub>2</sub> of the total digitalizing dose (TDD) as the initial dose, then give <sup>1</sup>/<sub>4</sub> of the TDD in each of two subsequent doses at 6- to 8-hour intervals. Obtain ECG 6 hours after each dose to assess potential toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Daily maintenance dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: 0.125 to 0.5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV, IM: 0.1 to 0.4 mg once daily (<b>Note:</b> IM not preferred due to severe injection site pain.)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Digitalizing (loading) dose: There are no dosage adjustments provided in the manufacturer's labeling for digitalizing dose; however, 50% to 70% of a digoxin dose is excreted unchanged in the urine. The following adjustments have been recommended in adults with end-stage renal disease (ESRD): Reduce usual dose by 50% (Aronoff 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer's labeling: Dosage reductions and close monitoring recommended; see product labeling for CrCl-specific dosage recommendation</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate dosing: The following adjustments have been recommended (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR: 30 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 75% of normal dose at normal intervals</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR: 10 to 29 mL/minute/1.73 m<sup>2</sup>: Administer 50% of normal dose at normal intervals <b>or</b> administer normal dose every 36 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">GFR: &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 25% of normal dose at normal intervals <b>or</b> administer normal dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Intermittent hemodialysis: Nondialyzable (0% to 5%). Administer 25% of normal dose at normal intervals <b>or</b> administer normal dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Peritoneal dialysis (PD): Administer 25% of normal dose at normal intervals <b>or</b> administer normal dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Continuous renal replacement therapy (CRRT): Administer 75% of normal dose at normal intervals; titrate to desired effect; monitor serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ESRD: If loading dose necessary, reduce by 50% (Aronoff 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Acute renal failure: Based on expert opinion, if patient in acute renal failure requires ventricular rate control (eg, in atrial fibrillation), consider alternative therapy. If loading digoxin becomes necessary, patient volume of distribution may be increased and reduction in loading dose may not be necessary; however, maintenance dosing will require adjustment as long as renal failure persists.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance dose (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 50 mL/minute: Administer 25% to 75% of normal daily dose (divided and given at normal intervals) or administer normal dose every 36 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: Administer 10% to 25% of normal daily dose (divided and given at normal intervals) or give normal dose every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): Administer 25% to 75% of the normal daily dose or administer normal dose every 36 hours; monitor serum concentrations.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: Not dialyzable; no supplemental dose necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Heart failure: Initial maintenance dose (Bauman 2006; Jusko 1974; Koup 1975): <b>Note:</b> The following suggested dosing recommendations are intended to achieve a target digoxin concentration of 0.7 ng/mL. Renal function estimated using Cockcroft-Gault formula.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;120 mL/minute: 0.25 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 80 to 120 mL/minute: Alternate between doses of 0.25 mg and 0.125 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 30 to 80 mL/minute: 0.125 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;30 mL/minute: 0.125 mg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> A contemporary digoxin dosing nomogram using creatinine clearance and ideal body weight or height has been published for determining the initial maintenance dose in patients with heart failure to achieve a target digoxin concentration of 0.7 ng/mL (Bauman 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160116\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lanoxin: 0.25 mg/mL (2 mL) [contains alcohol, usp, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lanoxin Pediatric: 0.1 mg/mL (1 mL) [contains alcohol, usp, propylene glycol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25 mg/mL (1 mL [DSC], 2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05 mg/mL (60 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Digitek: 125 mcg [scored; contains fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Digitek: 250 mcg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Digox: 125 mcg [scored; contains fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Digox: 250 mcg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lanoxin: 62.5 mcg [contains corn starch, fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lanoxin: 125 mcg [scored; contains fd&amp;c yellow #10 (quinoline yellow), fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lanoxin: 187.5 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lanoxin: 250 mcg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mcg, 250 mcg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160101\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052271\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer consistently with relationship to meals; avoid concurrent administration (ie, administer digoxin 1 hour before or 2 hours after) with meals high in fiber or pectin and with drugs that decrease oral absorption of digoxin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Oral solution: Only the calibrated manufacturer-provided dropper or a calibrated oral syringe should be used to measure the dose. For doses &lt;0.2 mL the manufacturer-provided dropper is not accurate and should not be used; use a calibrated oral syringe.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> IV: May be slowly administered IV over &ge;5 minutes (usually 5 to 10 minutes); avoid rapid IV infusion since this may result in systemic and coronary arteriolar vasoconstriction</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Vesicant; ensure proper needle or catheter placement prior to and during administration; avoid extravasation. If extravasation occurs, stop IV administration immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IM: Not usually recommended due to local irritation, pain, and tissue damage; if necessary, administer by deep injection followed by massage at the injection site. May cause intense pain.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160137\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect elixir, injection, and tablets from light. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052270\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of mild to moderate heart failure (HF) (Injection, oral solution: FDA approved in all ages; Tablets: FDA approved in ages &ge;5 years and adults); chronic atrial fibrillation (rate-control) (all dosage forms: FDA approved in adults). Has also been used for fetal tachycardia with or without hydrops; to slow ventricular rate in supraventricular tachyarrhythmias such as supraventricular tachycardias (SVT), excluding atrioventricular reciprocating tachycardia (AVRT). <b>Note:</b> Approved ages in pediatric population may vary with generic formulations; consult product specific labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160198\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-left:2em;\">Digoxin may be confused with Desoxyn, doxepin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lanoxin may be confused with Lasix, levothyroxine, Levoxyl, Levsinex, Lomotil, Mefoxin, naloxone, Xanax</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Digoxin is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older as first-line therapy for atrial fibrillation (due to more effective alternatives and potential for increased mortality) or as first-line therapy for heart failure (due to potential for increased mortality, questionable effects on risk of hospitalization, and lack of additional benefit when higher doses are used despite the increased risk of toxicity). If used, avoid doses greater than 0.125 mg/day due to decreased renal clearance of digoxin which may result in increased risk of toxic effects; further dose reductions may be warranted in patients with Stage 4 or 5 chronic kidney disease (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Digoxin (at doses greater than 0.125 mg/day) is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lanoxin [US, Canada, and multiple international markets] may be confused with Limoxin brand name for ambroxol [Indonesia] and amoxicillin [Mexico]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160195\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Accelerated junctional rhythm, asystole, atrial tachycardia with or without block, AV dissociation, first-, second- (Wenckebach), or third-degree heart block, facial edema, PR prolongation, PVCs (especially bigeminy or trigeminy), ST segment depression, ventricular tachycardia or ventricular fibrillation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Apathy, anxiety, confusion, delirium, depression, dizziness, fever, hallucinations, headache, mental disturbances</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Rash (erythematous, maculopapular [most common], papular, scarlatiniform, vesicular or bullous), pruritus, urticaria, angioneurotic edema </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, anorexia, diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ocular: Visual disturbances (blurred or yellow vision)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Laryngeal edema </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Asymmetric chorea, gynecomastia, thrombocytopenia, palpitation, intestinal ischemia, hemorrhagic necrosis of the intestines, vaginal cornification, eosinophilia, sexual dysfunction, diaphoresis </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160123\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to digoxin, other forms of digitalis, or any component of the formulation; ventricular fibrillation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160105\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Digoxin toxicity: Signs and symptoms of digoxin toxicity include anorexia, nausea, vomiting, visual changes, and cardiac arrhythmias; toxicity is usually associated with digoxin levels &gt;2 ng/mL, although symptoms may occur at lower levels. Patients at increased risk for digoxin toxicity include those with low body weight, advanced age, renal impairment, hypokalemia, hypercalcemia, or hypomagnesemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Extravasation: IV administration: Vesicant; ensure proper needle or catheter placement prior to and during administration; avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Proarrhythmic effects: Monitor for proarrhythmic effects (especially with digoxin toxicity)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Accessory bypass tract (eg, Wolff-Parkinson-White [WPW] syndrome): During an episode of atrial fibrillation or flutter in patients with an accessory bypass tract or pre-excitation syndrome, use has been associated with increased anterograde conduction down the accessory pathway leading to ventricular fibrillation; avoid use in such patients (ACLS [Neumar 2010]; AHA/ACC/HRS [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Acute coronary syndrome: Use with caution in patients with an acute MI; may increase myocardial oxygen demand and lead to ischemia. During an acute coronary syndrome, digoxin administered IV may be used to slow a rapid ventricular response and improve left ventricular (LV) function in the acute treatment of atrial fibrillation associated with severe LV function and heart failure or hemodynamic instability (AHA/ACC/HRS [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Atrial fibrillation: When used for rate control in patients with atrial fibrillation, monitor serum concentrations closely; may be associated with an increased risk of mortality especially when serum concentrations are not properly controlled (Vamos 2015). </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Beri beri heart disease: Patients with beri beri heart disease may fail to adequately respond to digoxin therapy; treat underlying thiamine deficiency concomitantly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy; toxicity may occur despite therapeutic digoxin concentrations (eg, &lt;2 ng/mL). Hypercalcemia may increase the risk of digoxin toxicity and hypocalcemia can nullify the effects of digoxin; maintain normocalcemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Heart failure: Digoxin should be considered for use only in heart failure (HF) with reduced ejection fraction (HFrEF) when symptoms remain despite guideline-directed medical therapy. It may also be considered in patients with both HF and atrial fibrillation; however, beta blockers may offer better ventricular rate control than digoxin (ACCF/AHA [Yancy 2013]). Withdrawal of digoxin in clinically stable patients with HF may lead to recurrence of HF symptoms (Packer 1993). Monitor serum concentrations closely; may be associated with an increased risk of mortality especially when serum concentrations are not properly controlled (Vamos 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypermetabolic states: Atrial arrhythmias associated with hypermetabolic (eg, hyperthyroidism) or hyperdynamic (hypoxia, arteriovenous shunt) states are very difficult to treat; treat underlying condition first. If digoxin is used, ensure digoxin toxicity does not occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Outflow obstruction may worsen due to the positive inotropic effects of digoxin; avoid use unless used to control ventricular response with atrial fibrillation. Digoxin is potentially harmful in the treatment of dyspnea in patients with HCM in the absence of atrial fibrillation (Gersh 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myocarditis: In a murine model of viral myocarditis, digoxin in high doses was shown to be detrimental (Matsumori 1999). If used in humans, therefore, digoxin should be used with caution and only at low doses (Frishman 2007). The manufacturer recommends avoiding the use of digoxin in patients with myocarditis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Preserved left ventricular function: Decreased cardiac output may occur in patients with preserved left ventricular systolic function, including restrictive or hypertrophic cardiomyopathy, constrictive pericarditis, amyloid heart disease, and acute cor pulmonale; in general, the manufacturer recommends to avoid use unless used to control ventricular response with atrial fibrillation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment needed. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sinus node disease and atrioventricular (AV) block: Because digoxin slows sinoatrial and AV conduction, the drug commonly prolongs the PR interval. Digoxin may cause severe sinus bradycardia or sinoatrial block particularly in patients with preexisting sinus node disease. Avoid use in patients with second- or third-degree heart block (except in patients with a functioning artificial pacemaker) (Yancy 2013); incomplete AV block (eg, Stokes-Adams attacks) may progress to complete block with digoxin administration. In such patients, if treatment with digoxin is necessary, consider the insertion of a pacemaker before treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thyroid disease: Use with caution in patients with hypothyroidism, higher digoxin concentrations may result due to significant reduction in digoxin clearance (Burk 2010). In patients with hyperthyroidism, lower digoxin concentrations may result due to an  increase in renal clearance of digoxin. No significant differences in absorption were seen in either thyroid condition compared with those with normal thyroid function (Burk 2010). <b>Note:</b> New-onset atrial fibrillation or exacerbation of ventricular arrhythmias should prompt evaluation of thyroid status.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infants: Newborn infants display considerable variability to their tolerance to digoxin; premature and immature infants are particularly sensitive to the effects of digoxin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Low body weight: Patients with decreased body weight are at an increased risk of drug-related toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elective electrical cardioversion: It is not necessary to routinely reduce or hold digoxin therapy prior to elective electrical cardioversion for atrial fibrillation; however, exclusion of digoxin toxicity (eg, clinical and ECG signs) is necessary prior to cardioversion. If signs of digoxin excess exist, withhold digoxin and delay cardioversion until toxicity subsides (AHA/ACC/HRS [January 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25856018\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Children are more likely to experience cardiac arrhythmia as a sign of excessive dosing. The most common are conduction disturbances or tachyarrhythmia (atrial tachycardia with or without block) and junctional tachycardia. Ventricular tachyarrhythmias are less common. In infants, sinus bradycardia may be a sign of digoxin toxicity. Any arrhythmia seen in a child on digoxin should be considered as digoxin toxicity. The gastrointestinal and central nervous system symptoms are not frequently seen in children.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160185\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160110\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13230&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">5-Aminosalicylic Acid Derivatives: May decrease the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acarbose: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adenosine: Digoxin may enhance the adverse/toxic effect of Adenosine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration.<b> Exceptions: </b>Amikacin; Kanamycin; Streptomycin; Tobramycin (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoquinolines (Antimalarial): May increase the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May increase the serum concentration of Cardiac Glycosides. Management: Reduce the dose of cardiac glycosides by 30% to 50%  or reduce the frequency of administration when initiating concomitant amiodarone therapy. Monitor for increased serum concentrations and toxic effects  of cardiac glycosides.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: May enhance the adverse/toxic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anagliptin: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anthracyclines: Cardiac Glycosides may diminish the cardiotoxic effect of Anthracyclines. Anthracyclines may decrease the serum concentration of Cardiac Glycosides. The effects of liposomal formulations may be unique from those of the free drug, as liposomal formulation have unique drug disposition and toxicity profiles, and liposomes themselves may alter digoxin absorption/distribution. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antithyroid Agents: May increase the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barnidipine: May enhance the adverse/toxic effect of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benidipine: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benznidazole: May enhance the adverse/toxic effect of Products Containing Propylene Glycol.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the bradycardic effect of Cardiac Glycosides.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Cardiac Glycosides.<b> Exceptions: </b>Colesevelam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Digoxin. Management: In patients initiating digoxin during boceprevir treatment, initiate at the lowest possible digoxin dose, monitor serum digoxin concentrations, and titrate carefully due to a possible risk of elevated digoxin concentrations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the bradycardic effect of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May enhance the AV-blocking effect of Cardiac Glycosides. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: Digoxin may enhance the bradycardic effect of Carvedilol. Carvedilol may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloNIDine: May enhance the AV-blocking effect of Cardiac Glycosides. Sinus node dysfunction may also be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: Digoxin may increase the serum concentration of Colchicine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: May increase the serum concentration of Digoxin. Management: See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diacerein: May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: Digoxin may enhance the AV-blocking effect of Dronedarone. Digoxin may also enhance the other electrophysiologic effects of Dronedarone. Dronedarone may increase the serum concentration of Digoxin.  Management: Avoid concurrent use of digoxin when possible.  If concurrent use is necessary, reduce adult digoxin dose by 50%,  monitor digoxin concentration closely, and increase monitoring for both clinical response to therapy and the occurrence of adverse effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edrophonium: May enhance the AV-blocking effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: May increase the serum concentration of Digoxin. Management: In patients receiving digoxin, measure digoxin serum concentrations prior to initiating eliglustat.  Preemptively reduce digoxin doses by 30% and continue monitoring following eliglustat initiation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPHEDrine (Nasal): Cardiac Glycosides may enhance the arrhythmogenic effect of EPHEDrine (Nasal). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPHEDrine (Systemic): May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Epoprostenol: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: May increase the serum concentration of Digoxin. Management: Monitor serum digoxin concentrations and adjust dose as needed. In patients initiating a regimen of digoxin with etravirine, digoxin should be initiated at the lowest dose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flecainide: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glecaprevir and Pibrentasvir: May increase the serum concentration of Digoxin. Management: Measure serum digoxin concentrations before initiating glecaprevir/pibrentasvir. Reduce digoxin concentrations by decreasing the digoxin dose by approximately 50% or by modifying the dosing frequency; continue monitoring during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Systemic): May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of Cardiac Glycosides. Management: Consider preemptive cardiac glycoside dose adjustments with initiation / changes / discontinuation of itraconazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kaolin: May decrease the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenalidomide: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: May enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, levosulpiride may diminish symptoms of cardiac glycoside-related toxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Licorice: May enhance the adverse/toxic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, cardiac glycoside toxicity may be enhanced by the hypokalemic and hypomagnesemic effect of loop diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May increase the serum concentration of Cardiac Glycosides.<b> Exceptions: </b>Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaraminol: May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midodrine: Cardiac Glycosides may enhance the bradycardic effect of Midodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of Digoxin. Management: Measure serum digoxin concentration 1-2 weeks following mifepristone initiation, and in accordance with normal clinical practice thereafter, adjusting dose as needed.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Milnacipran: May enhance the adverse/toxic effect of Digoxin. The risk of postural hypotension and tachycardia may be increased, particularly with IV digoxin. Management: Avoid concurrent use of intravenous (IV) digoxin in patients receiving milnacipran. Use caution when using oral digoxin and milnacipran together, monitoring closely for possible postural hypotension and tachycardia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: May increase the serum concentration of Digoxin. Management: Consider using the lowest dose of digoxin when initiating concurrent mirabegron.  Monitor serum digoxin concentrations closely to help guide digoxin dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nefazodone: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ombitasvir, Paritaprevir, and Ritonavir: May increase the serum concentration of Digoxin. Management: When initiating the ombitasvir/paritaprevir/ritonavir combination product in patients taking digoxin, decrease the digoxin dose by 30% to 50% and monitor serum digoxin levels to determine further dose adjustments.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parathyroid Hormone: May enhance the adverse/toxic effect of Cardiac Glycosides. More specifically, Parathyroid Hormone-related hypercalcemia may predispose to digitalis toxicity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paricalcitol: May enhance the adverse/toxic effect of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PenicillAMINE: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Polyethylene Glycol 3350: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Polyethylene Glycol 4000: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: May diminish the therapeutic effect of Cardiac Glycosides. In particular, the inotropic effects of digoxin appear to be diminished. Potassium-Sparing Diuretics may increase the serum concentration of Cardiac Glycosides. This particular effect may be unique to Spironolactone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May increase the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: May increase the serum concentration of Cardiac Glycosides. Management: Upon quinidine initiation, consider reducing cardiac glycoside dose by 25% to 50%, with continued monitoring of glycoside serum concentrations and clinical response until the quinidine reaches steady state (5-10 days).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: May enhance the bradycardic effect of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reserpine: May enhance the adverse/toxic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of Digoxin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roxithromycin: May increase the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SITagliptin: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: May increase the serum concentration of Digoxin. Spironolactone (and/or its metabolites) may also interfere with the assays used to determine Digoxin concentrations, falsely increasing or decreasing Digoxin concentrations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the serum concentration of Digoxin. Specifically, sucralfate may decrease the absorption of digoxin. Management: Administer digoxin at least 2 hours before or at least 6 hours after sucralfate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Digoxin. Management: Use the lowest possible digoxin dose when starting therapy in a patient who is being treated with telaprevir, and monitor clinical response and serum concentrations closely for further dosing adjustments.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telmisartan: May increase the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, cardiac glycoside toxicity may be enhanced by the hypokalemic and hypomagnesemic effect of thiazide diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valbenazine: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vandetanib: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: May increase the serum concentration of Digoxin. Management: Avoid coadministration of vemurafenib and digoxin when possible.  If concomitant use cannot be avoided, consider digoxin dose reduction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May increase the serum concentration of Digoxin. Management: Administer digoxin at least 6 hours before venetoclax when concomitant therapy is required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vilazodone: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D Analogs: May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160139\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Digoxin peak serum concentrations may be decreased if taken with food. Meals containing increased fiber (bran) or foods high in pectin may decrease oral absorption of digoxin.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160112\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9729170\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Digoxin crosses the placenta and serum concentrations are similar in the mother and fetus at delivery. Digoxin is recommended in the treatment of fetal tachycardia determined to be SVT. In pregnant women, use of digoxin is recommended as a first-line agent for chronic treatment of highly symptomatic SVT; the lowest effective dose is recommended (Page [ACC/AHA/HRS 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052265\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate and rhythm, periodic ECG; follow serum potassium, magnesium, and calcium closely (especially in patients receiving diuretics or amphotericin or patient with a history of hypokalemia or hypomagnesemia); decreased serum potassium and magnesium, or increased serum magnesium and calcium may increase digoxin toxicity; assess renal function (serum BUN, S<sub>cr</sub>) in order to adjust dose; obtain serum drug concentrations at least 8 to 12 hours after a dose, preferably prior to next scheduled dose. Observe patients for noncardiac signs of toxicity, confusion, and depression.</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Therapeutic drug monitoring: Digoxin serum concentrations are monitored because digoxin possesses a narrow therapeutic serum concentration range; the therapeutic endpoint is difficult to quantify and digoxin toxicity may be life-threatening. Digoxin serum concentrations should be drawn <b>at least 6 to 8 hours after the previous dose, regardless of route of administration (optimally 12 to 24 hours after a dose)</b>. <b>Note:</b> Serum digoxin concentrations may decrease in response to exercise due to increased skeletal muscle uptake; a period of rest (eg, ~2 hours) after exercise may be necessary prior to drawing serum digoxin concentrations.</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Initiation of therapy: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>If a loading dose is given:</b> Digoxin serum concentration may be drawn within 12 to 24 hours after the initial loading dose administration. Concentrations drawn this early may confirm the relationship of digoxin plasma concentrations and response but are of little value in determining maintenance doses. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>If a loading dose is not given:</b> Digoxin serum concentration should be obtained after 3 to 5 days of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Maintenance therapy: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>Trough</b> concentrations should be followed just prior to the next dose or at a minimum of 6 to 8 hours after last dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Digoxin serum concentrations should be obtained within 5 to 7 days (approximate time to steady-state) after any dosage changes. Continue to obtain digoxin serum concentrations 7 to 14 days after any change in maintenance dose. <b>Note:</b> Time to steady state will be longer in patients with decreased renal function (eg, premature neonates or patients with renal impairment). In patients with end-stage renal disease, it may take 15 to 20 days to reach steady-state. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Patients who are receiving electrolyte-altering medications such as diuretics, serum potassium, magnesium, and calcium should be monitored closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">Digoxin serum concentrations should be obtained whenever any of the following conditions occur: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">Questionable patient compliance or to evaluate clinical deterioration following an initial good response </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">Changing renal function </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">Suspected digoxin toxicity </p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">Initiation or discontinuation of therapy with drugs (eg, amiodarone, quinidine, verapamil) which potentially interact with digoxin.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">Any disease changes (eg, thyroid disease)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052269\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Digoxin therapeutic serum trough concentrations:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heart failure: 0.5 to 0.9 ng/mL (ACCF/AHA [Yancy 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: &lt;0.5 ng/mL (SI: &lt;0.6 nmol/L); probably indicates underdigitalization unless there are special circumstances</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toxic: &gt;2 ng/mL; (SI: &gt;2.6 nmol/L). <b>Note:</b> Serum concentration must be used in conjunction with clinical symptoms and ECG to confirm diagnosis of digoxin intoxication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin-like immunoreactive substance (DLIS) may cross-react with digoxin immunoassay and falsely increase serum concentrations. DLIS has been found in patients with renal and liver disease, heart failure, neonates, and pregnant women (3rd trimester).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160104\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heart failure: Inhibition of the sodium/potassium ATPase pump in myocardial cells results in a transient increase of  intracellular sodium, which in turn promotes calcium influx via the sodium-calcium exchange pump leading to increased contractility. May improve baroreflex sensitivity (Gheorghiade 1991).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Supraventricular arrhythmias: Direct suppression of the AV node conduction to increase effective refractory period and decrease conduction velocity - positive inotropic effect, enhanced vagal tone, and decreased ventricular rate to fast atrial arrhythmias. Atrial fibrillation may decrease sensitivity and increase tolerance to higher serum digoxin concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160122\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Heart rate control: Oral: 1 to 2 hours; IV: 5 to 60 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Heart rate control: Oral: 2 to 8 hours; IV: 1 to 6 hours; <b>Note:</b> In patients with atrial fibrillation, median time to ventricular rate control in one study was 6 hours (range: 3 to 15 hours) (Siu, 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Adults: 3 to 4 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: By passive nonsaturable diffusion in the upper small intestine; food may delay, but does not affect extent of absorption </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Normal renal function: 6 to 7 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>d</sub>: Extensive to peripheral tissues, with a distinct distribution phase which lasts 6 to 8 hours; concentrates in heart, liver, kidney, skeletal muscle, and intestines. Heart/serum concentration is 70:1. Pharmacologic effects are delayed and do not correlate well with serum concentrations during distribution phase. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hyperthyroidism: Increased V<sub>d</sub></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hyperkalemia, hyponatremia: Decreased digoxin distribution to heart and muscle </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypokalemia: Increased digoxin distribution to heart and muscles </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Concomitant quinidine therapy: Decreased V<sub>d</sub></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chronic renal failure: 4 to 6 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Decreased sodium/potassium ATPase activity - decreased tissue binding </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates, full-term: 7.5 to 10 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 16 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 7 L/kg, decreased with renal disease </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~25%; in uremic patients, digoxin is displaced from plasma protein binding sites </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Via sequential sugar hydrolysis in the stomach or by reduction of lactone ring by intestinal bacteria (in ~10% of population, gut bacteria may metabolize up to 40% of digoxin dose); once absorbed, only ~16% is metabolized to 3-beta-digoxigenin, 3-keto-digoxigenin, and glucuronide and sulfate conjugates; metabolites may contribute to therapeutic and toxic effects of digoxin; metabolism is reduced with decompensated HF</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral (formulation dependent): Elixir: 70% to 85%; Tablet: 60% to 80% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination (age, renal and cardiac function dependent): </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: Premature: 61 to 170 hours; Full-term: 35 to 45 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants: 18 to 25 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: 18 to 36 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 36 to 48 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults, anephric: 3.5 to 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Parent drug: 38 hours; Metabolites: Digoxigenin: 4 hours; Monodigitoxoside: 3 to 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: 1 to 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (50% to 70% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160125\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Digoxin Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg/mL (2 mL): $7.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Digoxin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05 mg/mL (60 mL): $168.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Lanoxin Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg/mL (2 mL): $101.47</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Lanoxin Pediatric Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg/mL (1 mL): $101.47</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Digitek Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (100): $230.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg (100): $230.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Digox Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (100): $230.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg (100): $230.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Digoxin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (100): $210.63</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg (100): $207.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Lanoxin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">62.5 mcg (100): $1,490.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mcg (100): $1,490.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">187.5 mcg (100): $1,490.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg (100): $1,490.83</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160127\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Agoxin (BD);</li>\n      <li>Cadef Elixir Pediatric (KR);</li>\n      <li>Cardcor (BR, LI);</li>\n      <li>Cardiacin (TW);</li>\n      <li>Cardigo (LK);</li>\n      <li>Cardiogoxin (AR);</li>\n      <li>Cardioxin (PH);</li>\n      <li>Cardoxin (IL);</li>\n      <li>Centoxin (BD);</li>\n      <li>Digosin (JP, KR);</li>\n      <li>Digox (PH);</li>\n      <li>Digoxicor (LV);</li>\n      <li>Digoxil (PY);</li>\n      <li>Digoxin (PL);</li>\n      <li>Digoxin NI (ID);</li>\n      <li>Digoxin &rdquo;Dak&rdquo; (DK);</li>\n      <li>Digoxin-Actavis (HK);</li>\n      <li>Digoxin-Sandoz (BF, BJ, CH, CI, ET, GH, GM, GN, ID, JP, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Digoxin-Zori (IL);</li>\n      <li>Digoxina (CO, ES, GT, HN, NI, PE);</li>\n      <li>Digoxine Nativelle (LU);</li>\n      <li>Digoxine Navtivelle (FR);</li>\n      <li>Dilacor (BG);</li>\n      <li>Dilanacin (CY, EG, IQ, SD);</li>\n      <li>Dixcool (LK);</li>\n      <li>Eudigox (IT);</li>\n      <li>Fargoxin (ID);</li>\n      <li>Grekin (LI);</li>\n      <li>Grexin (TH);</li>\n      <li>Ke Li (CN);</li>\n      <li>Lanacordin (ES);</li>\n      <li>Lanibos (KW, SA);</li>\n      <li>Lanicor (AR, AT, BB, BF, BH, BJ, BM, BS, BZ, CI, CY, CZ, DE, EC, EG, ET, GH, GM, GN, GR, GY, HR, IQ, IR, JM, KE, LI, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, OM, SC, SD, SL, SN, SR, SY, TN, TT, TZ, UG, VE, YE, ZM, ZW);</li>\n      <li>Lanikor (RU);</li>\n      <li>Lanioxin (IS);</li>\n      <li>Lanitop (SA);</li>\n      <li>Lanoxin (AE, AR, AU, BB, BD, BE, BF, BH, BJ, BM, BS, BZ, CI, CR, CY, DO, EG, ET, GB, GH, GM, GN, GR, GT, GY, HK, HN, IE, IL, IN, IQ, IR, IT, JM, JO, JP, KE, KR, KW, LB, LI, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PH, PK, PT, PY, QA, RU, SA, SC, SD, SE, SG, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, UY, YE, ZM, ZW);</li>\n      <li>Lanoxin PG (NZ, QA);</li>\n      <li>Lenoxin (DE);</li>\n      <li>Mapluxin (MX);</li>\n      <li>Myoxin (BD);</li>\n      <li>Purgoxin (ZA);</li>\n      <li>Sigmaxin (AU);</li>\n      <li>Toloxin (TH);</li>\n      <li>Valvulan (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Vidaxil (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults [published online October 8, 2015]. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Antman EM, Anbe DT, Armstrong PW, et al, &quot;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction),&quot; <i>Circulation</i>, 2004, 110(9):e82-292.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/15339869/pubmed\" target=\"_blank\" id=\"15339869\">15339869</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bakir M and Bilgic A, &ldquo;Single Daily Dose of Digoxin for Maintenance Therapy of Infants and Children With Cardiac Disease: Is It Reliable?&rdquo; <i>Pediatr Cardiol</i>, 1994, 15(5):229-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/7997427 /pubmed\" target=\"_blank\" id=\"7997427 \">7997427 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauman JL, DiDomenico RJ, Viana M, Fitch M. A method of determining the dose of digoxin for heart failure in the modern era. <i>Arch Intern Med</i>. 2006;166(22):2539-2545.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/17159022 /pubmed\" target=\"_blank\" id=\"17159022 \">17159022 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bendayan R and McKenzie MW, &ldquo;Digoxin Pharmacokinetics and Dosage Requirements in Pediatric Patients,&rdquo; <i>Clin Pharm</i>, 1983, 2(3):224-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/6349908/pubmed\" target=\"_blank\" id=\"6349908\">6349908</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al, &ldquo;ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias--Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias),&rdquo; <i>Circulation</i>, 2003, 108(15):1871-909.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/14557344/pubmed\" target=\"_blank\" id=\"14557344\">14557344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burk O, Brenner SS, Hofmann U, et al. The Impact of Thyroid Disease on the regulation, expression, and function of ABCB! (MDRa/P-glycoprotein) and consequences for the disposition of digoxin. <i>Clin Pharm Ther</i>. 2010;88(5):685-694.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/20844484/pubmed\" target=\"_blank\" id=\"20844484\">20844484</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Escudero C, Carr R, Sanatani S. The medical management of pediatric arrhythmias. <i>Curr Treat Options Cardiovasc Med</i>. 2012;14(5):455-472.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/22907424/pubmed\" target=\"_blank\" id=\"22907424\">22907424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    European Heart Rhythm Association; Heart Rhythm Society, Fuster V, et al, &quot;ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation &minus; Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation),&quot; <i>J Am Coll Cardiol</i>, 2006, 48(4):854-906.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/16904574/pubmed\" target=\"_blank\" id=\"16904574\">16904574</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frishman WH, Zeidner J, Naseer N. Diagnosis and Management of Viral Myocarditis. <i>Curr Treat Options Cardiovas Med</i>. 2007;9:450-464.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/18221597/pubmed\" target=\"_blank\" id=\"18221597\">18221597</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2011;124(24):e783-831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/22068434/pubmed\" target=\"_blank\" id=\"22068434\">22068434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gheorghiade M and Ferguson D. Digoxin. A neurohormonal modulator in heart failure? <i>Circulation</i>. 1991;84(5):2181-2186.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/1834367/pubmed\" target=\"_blank\" id=\"1834367\">1834367</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hunt SA, Abraham WT, Chin MH, et al, &quot;2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&quot; <i>J Am Coll Cardiol</i>, 2009, 53(15):e1-e90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/19358937/pubmed\" target=\"_blank\" id=\"19358937\">19358937</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>. doi:10.1161/CIR.0000000000000041.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span><span class=\"doi\">10.1161/CIR.0000000000000041</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johne A, Brockmoller J, Bauer S, et al, &ldquo;Pharmacokinetic Interaction of Digoxin With an Herbal Extract From St John's Wort (<i>Hypericum perforatum</i>),&rdquo; <i>Clin Pharmacol Ther</i>, 1999, 66(4):338-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/10546917/pubmed\" target=\"_blank\" id=\"10546917\">10546917</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jusko WJ, Szefler SJ, Goldfarb AL. Pharmacokinetic design of digoxin dosage regimens in relation to renal function.<i> J Clin Pharmacol</i>. 1974;14(10):525-535.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/4430731 /pubmed\" target=\"_blank\" id=\"4430731 \">4430731 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koup JR, Jusko WJ, Elwood CM, Kohli RK. Digoxin pharmacokinetics: role of renal failure in dosage regimen design. <i>Clin Pharmacol Ther</i>. 1975;18(1):9-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/1149366 /pubmed\" target=\"_blank\" id=\"1149366 \">1149366 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kugler JD, Danford DA. Management of infants, children, and adolescents with paroxysmal supraventricular tachycardia. <i>J Pediatr</i>. 1996;129(3):324-338.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/8804320/pubmed\" target=\"_blank\" id=\"8804320\">8804320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lanoxin injection (digoxin) [prescribing information]. Greenville, NC: DSM Pharmaceuticals, Inc; May 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lanoxin tablets (digoxin) [prescribing information]. Greenville, NC: DSM Pharmaceuticals, Inc; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Latifi S, Lidsky K, and Blumer JL, &quot;Pharmacology of Inotropic Agents in Infants and Children,&quot; <i>Prog Pediatr Cardiol</i>, 2000, 12(1):57-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/11114547/pubmed\" target=\"_blank\" id=\"11114547\">11114547</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matsumori A, Igata H, Ono K, et al. High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity. <i>Jpn Circ J</i>. 1999;63:934-990.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/10614837/pubmed\" target=\"_blank\" id=\"10614837\">10614837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2011;123(6):e236.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/20956224/pubmed\" target=\"_blank\" id=\"20956224\">20956224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Sullivan JJ, Gardiner HM, Wren C. Digoxin or flecainide for prophylaxis of supraventricular tachycardia in infants? <i>J Am Coll Cardiol</i>. 1995;26(4):991-994.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/7560629/pubmed\" target=\"_blank\" id=\"7560629\">7560629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Packer M, Gheorghiade M, Young JB, et al, &ldquo;Withdrawal of Digoxin From Patients With Chronic Heart Failure Treated With Angiotensin-converting Enzyme Inhibitors, RADIANCE Study,&rdquo; <i>N Engl J Med</i>, 1993, 329(1):1-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/8505940/pubmed\" target=\"_blank\" id=\"8505940\">8505940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2016;67(13):e27-e115. doi: 10.1016/j.jacc.2015.08.856.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/26409259/pubmed\" target=\"_blank\" id=\"26409259\">26409259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park MK, &ldquo;Use of Digoxin in Infants and Children With Specific Emphasis on Dosage,&rdquo; <i>J Pediatr</i>, 1986, 108(6):871-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/3012054/pubmed\" target=\"_blank\" id=\"3012054\">3012054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ross RD, &quot;Medical Management of Chronic Heart Failure in Children,&quot; <i>Am J Cardiovasc Drugs</i>, 2001, 1(1):37-44.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanatani S, Potts JE, Reed JH, et al. The study of antiarrhythmic medications in infancy (SAMIS): a multicenter, randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants. <i>Circ Arrhythm Electrophysiol</i>. 2012;5(5):984-991.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/22962431/pubmed\" target=\"_blank\" id=\"22962431\">22962431</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siu CW, Lau CP, Lee WL, et al, &quot;Intravenous Diltiazem Is Superior to Intravenous Amiodarone or Digoxin for Achieving Ventricular Rate Control in Patients With Acute Uncomplicated Atrial Fibrillation,&quot; <i>Crit Care Med</i>, 2009, 37(7):2174-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/19487941/pubmed\" target=\"_blank\" id=\"19487941\">19487941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. <i>Eur Heart J</i>. 2015 May 4. pii: ehv143. [Epub ahead of print].<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/25939649/pubmed\" target=\"_blank\" id=\"25939649\">25939649</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/digoxin-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13230 Version 233.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F160142\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F160143\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1052266\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F15163298\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1052258\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F160116\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F160101\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1052271\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F160137\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1052270\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F160198\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F160195\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F160123\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F160105\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25856018\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F160185\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F160110\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F160139\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F160112\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9729170\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1052265\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1052269\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F160104\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F160122\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F160125\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F160127\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13230|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=digoxin-drug-information\" class=\"drug drug_general\">Digoxin: Drug information</a></li><li><a href=\"topic.htm?path=digoxin-patient-drug-information\" class=\"drug drug_patient\">Digoxin: Patient drug information</a></li></ul></div></div>","javascript":null}